Evidence map›Paper›PMID 38287960›Full record

ArticleFrontiers in microbiology2023

Penglei Wang, Yongming Li, Lei Gao, Xiang Tang, Dandian Zheng, Kuihai Wu, Luxia Wang, Penghao Guo, Feng Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Molecular Epidemiology and Antifungal Susceptibility ofInfection and drug resistance · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Penglei Wang *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, Guangzhou, China.
Yongming Li *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, Guangzhou, China.
Lei GaoMicroscopy Core Facility, Biomedical Research Core Facilities, Westlake University, Hangzhou, China.
Xiang TangIntensive Care Unit, Guangzhou First People's Hospital, Guangzhou, China.
Dandian ZhengDepartment of Hematology Oncology, Jieyang City People's Hospital, Jieyang, China.
Kuihai WuClinical Medicine Laboratory, Foshan City First People's Hospital, Foshan, China.
Luxia WangClinical Medicine Laboratory, Southern Military Region General Hospital, Guangzhou, China.
Penghao GuoClinical Medicine Laboratory, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China.
Feng YeState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The burden of cryptococcosis in mainland China is enormous. However, the Methods: From January 1, 2010, to March 31, 2019, clinical strains of Results: A total of 84 strains were collected, mostly from male and young or middle-aged adult patients. Pulmonary and cerebral infections (82.1%) were most common. All strains were Conclusion: Phenotypically variant and non-wild-type strains were found in Guangdong, and a significant proportion of these strains had MIC values near the ECV values towards the 6 antifungal drugs, and resistance was observed for 4 out of 6 drugs. The molecular type was highly homogeneous but compositionally diverse, with rare types found. Enhanced surveillance of the aetiology and evolution and continuous monitoring of antifungal susceptibility are needed to provide references for decision-making in the health sector and optimization of disease prevention and control.

Indexed as

antifungal susceptibility testCryptococcusgenetic evolution analysismolecular epidemiologyvirulence factor

Identifiers

PMID38287960
PMCPMC10823435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.